SCHEMBL497932

SCHEMBL497932

COC(=O)c1c(C)nnn1-c1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 4/20 0.44
GAA P10253 2/20 0.40
NR4A2 P43354 2/20 0.40
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
MAPK14 Q16539 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12474252 0.84 PDE4B (0.48) NPSR1ALDH1A1TP53HTTPDE4B
SCHEMBL19810784 0.82 NR1H4 (0.42) NPSR1ALDH1A1GAANR4A2TP53
SCHEMBL498006 0.81 GPBAR1 (0.47) NPSR1ALDH1A1NR4A2TP53HTT
SCHEMBL28906183 0.78 ALDH1A1 (0.54) ALDH1A1TP53POLBKDR
SCHEMBL16697590 0.74 GAA (0.49) NPSR1ALDH1A1GAATP53HTT
SCHEMBL16697431 0.72 SLC5A1 (0.46) ALDH1A1GAATP53HTTROCK1
SCHEMBL28906175 0.72 ALDH1A1 (0.51) ALDH1A1HTT
SCHEMBL1097175 0.71 NR1H4 (0.41) NPSR1ALDH1A1GAANR4A2POLB
SCHEMBL497636 0.71 NR1H4 (0.44) NPSR1ALDH1A1GAATP53PDE4A
SCHEMBL903085 0.71 NPSR1 (0.37) NPSR1ALDH1A1GAAHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 NPSR1 744/4885ALDH1A1 2294/4885GAA 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.